Albert M. Kim, MD, PhD

Adjunct Instructor, Boston University Chobanian & Avedisian School of Medicine

Biography

Dr. Kim is an accomplished physician-scientist with expertise in cardiovascular disease, translational medicine, and drug development. He earned his undergraduate degree in biomedical engineering from Harvard, MD and PhD degrees from UCLA, completed internal medicine residency at Brigham and Women's Hospital, cardiology fellowship training at MGH, and clinical cardiac electrophysiology training at UCSF. He joined the UCSF faculty and subsequently transitioned to the pharmaceutical industry as a Senior Translational Medicine Expert at Novartis, where he led small molecule and biologic asset programs for hyperlipidemia, inflammation, atherosclerosis, and arrhythmia indications. In 2013 he joined the Pfizer Cardiovascular and Metabolic (CVMET) Research Unit in Cambridge, MA and has served in multiple leadership roles over the past 4 years. He currently serves as VP, Clinical Research Head for CVMET, and oversees clinical research efforts for cardiometabolic diseases such as NASH, diabetes, obesity and heart failure. He has served in advisory and supervisory roles for cardiovascular safety and pharmacovigilance activities, and worked at the FDA in the Division of Cardiac Devices as a medical reviewer and project lead for the industry guidance document on catheter ablation for atrial fibrillation. Beyond his roles at Pfizer, he also holds academic appointments in the VA Boston Cardiac Electrophysiology Section, at Boston University, and at Harvard Medical School.

Publications

  • Published 1/17/2023

    Saxena AR, Lyle SA, Khavandi K, Qiu R, Whitlock M, Esler WP, Kim AM. A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes. Diabetes Obes Metab. 2023 Apr; 25(4):992-1001. PMID: 36515213.

    Read at: PubMed

  • Published 10/11/2021

    Calle RA, Amin NB, Carvajal-Gonzalez S, Ross TT, Bergman A, Aggarwal S, Crowley C, Rinaldi A, Mancuso J, Aggarwal N, Somayaji V, Inglot M, Tuthill TA, Kou K, Boucher M, Tesz G, Dullea R, Bence KK, Kim AM, Pfefferkorn JA, Esler WP. ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials. Nat Med. 2021 10; 27(10):1836-1848. PMID: 34635855.

    Read at: PubMed

  • Published 6/14/2021

    Saxena AR, Gorman DN, Esquejo RM, Bergman A, Chidsey K, Buckeridge C, Griffith DA, Kim AM. Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial. Nat Med. 2021 06; 27(6):1079-1087. PMID: 34127852.

    Read at: PubMed

  • Published 11/27/2019

    Amin NB, Carvajal-Gonzalez S, Purkal J, Zhu T, Crowley C, Perez S, Chidsey K, Kim AM, Goodwin B. Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis. Sci Transl Med. 2019 11 27; 11(520). PMID: 31776293.

    Read at: PubMed

  • Published 3/19/2019

    Roth Flach RJ, Su C, Bollinger E, Cortes C, Robertson AW, Opsahl AC, Coskran TM, Maresca KP, Keliher EJ, Yates PD, Kim AM, Kalgutkar AS, Buckbinder L. Myeloperoxidase inhibition in mice alters atherosclerotic lesion composition. PLoS One. 2019; 14(3):e0214150. PMID: 30889221.

    Read at: PubMed

View All 29 Publications:   View Full Profile in BUMC

Websites

Education

  • University of California, Los Angeles, MD
  • University of California, Los Angeles, PhD
  • Harvard College, AB

View all profiles